← back to search

Brookie M. Best

University of San Diego · US
Area of research
Infectious Diseases · Public Health, Environmental and Occupational Health
Research interest
Research interests include HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, Pregnancy and Medication Impact, and HIV Research and Treatment.
h-index
45
citations
6,430
works
192
NIH funding
primary concept
email

Recent publications

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
The Lancet HIV 2025cited by 10position: middledoi
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
The Lancet HIV 2024cited by 26position: middledoi
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
The Lancet HIV 2024cited by 23position: middledoi
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
The Lancet HIV 2023cited by 27position: middledoi
An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis
Journal of Pediatric Gastroenterology and Nutrition 2023cited by 17position: middledoi
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s
Antimicrobial Agents and Chemotherapy 2023cited by 15position: middledoi
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
The Lancet 2021cited by 157position: middledoi
Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial
The Journal of Pediatrics 2021cited by 50position: middledoi
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV
AIDS 2021cited by 27position: lastdoi
Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir
Clinical Pharmacokinetics 2021cited by 24position: middledoi
Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement
Clinical Pharmacology & Therapeutics 2020cited by 48position: middledoi
Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV
Clinical Pharmacokinetics 2020cited by 27position: middledoi
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling
Clinical Pharmacokinetics 2020cited by 24position: middledoi
Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy
The Journal of Clinical Pharmacology 2020cited by 16position: middledoi
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
The Lancet HIV 2019cited by 61position: middledoi
Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir
The Journal of Clinical Pharmacology 2019cited by 46position: middledoi
Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk
PEDIATRICS 2018cited by 179position: middledoi
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
AIDS 2018cited by 104position: middledoi
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
AIDS 2018cited by 68position: middledoi
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study
Clinical Infectious Diseases 2017cited by 103position: middledoi
Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial)
Contemporary Clinical Trials 2016cited by 68position: middledoi
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
JAIDS Journal of Acquired Immune Deficiency Syndromes 2016cited by 55position: middledoi
Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
Frontiers in Pharmacology 2016cited by 19position: middledoi
Pharmacokinetics of tenofovir during pregnancy and postpartum
HIV Medicine 2015cited by 76position: firstdoi
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women
JAIDS Journal of Acquired Immune Deficiency Syndromes 2015cited by 48position: middledoi
Obstetric Pharmacokinetic Dosing Studies are Urgently Needed
Frontiers in Pediatrics 2014cited by 81position: lastdoi
Raltegravir Pharmacokinetics During Pregnancy
JAIDS Journal of Acquired Immune Deficiency Syndromes 2014cited by 80position: middledoi
Protecting the Fetus Against HIV Infection: A Systematic Review of Placental Transfer of Antiretrovirals
Clinical Pharmacokinetics 2014cited by 74position: lastdoi
Variability in Metabolism of Imipramine and Desipramine Using Urinary Excretion Data†
Journal of Analytical Toxicology 2014cited by 14position: middledoi
Randomized Trial of Central Nervous System–Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder
Clinical Infectious Diseases 2013cited by 130position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Edmund V. Capparelli · University of California San Diego12 papers (2012–2023) · 10 papers (2013–2023)Mark Mirochnick · Boston University9 papers (2014–2021)Tim R. Cressey · ChiangRai Prachanukroh Hospital9 papers (2013–2023)Elizabeth Smith · University of Toledo9 papers (2013–2021)Jiajia Wang · Guangzhou University of Chinese Medicine8 papers (2013–2021)Sandra Burchett · Eunice Kennedy Shriver National Institute of Child Health and Human Development8 papers (2013–2021)Jeremiah D. Momper · University of California San Diego8 papers (2018–2021)Mark Mirochnick · Boston University7 papers (2013–2023)David E. Shapiro · Center for Cancer Research7 papers (2013–2023)Nahida Chakhtoura · National Institute of Child Health6 papers (2016–2023) · 4 papers (2015–2023)Ahizechukwu C. Eke · University of New Mexico4 papers (2020–2023)Régis Kreitchmann · Eunice Kennedy Shriver National Institute of Child Health and Human Development4 papers (2013–2016) · 3 papers (2016–2023) · 3 papers (2019–2021)Natella Rakhmanina · George Washington University3 papers (2019–2021)Elizabeth Hawkins · Creighton University3 papers (2013–2015)John N. van den Anker · George Washington University3 papers (2019–2021) · 3 papers (2019–2021)